Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma - Wikidata - thesis-toulmin - TriplyDB

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

http://www.wikidata.org/entity/Q28472048

about

Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer The mTOR signalling pathway in human cancer Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma Targeting the mTOR signaling network for cancer therapy PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets The search for antiaging interventions: from elixirs to fasting regimens Novel delivery strategies for glioblastoma Will kinase inhibitors make it as glioblastoma drugs?Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation The role of mTOR signaling in Alzheimer disease PI3K/PTEN signaling in angiogenesis and tumorigenesis Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development A melanoma molecular disease model Predictive and prognostic molecular markers for cancer medicine Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma The LKB1-AMPK pathway: metabolism and growth control in tumour suppression Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy Immunohistochemical assessment of protein phosphorylation state: the dream and the reality Lipid metabolism emerges as a promising target for malignant glioma therapy.EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry.Incorporating molecular tools into early-stage clinical trials An approach to analyse the specific impact of rapamycin on mRNA-ribosome association.Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.Therapeutic strategies for inhibiting invasion in glioblastoma.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.Phase II study of everolimus in metastatic urothelial cancer.Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival The intestinal TORC2 signaling pathway contributes to associative learning in Caenorhabditis elegans.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.

P2860

Q21245750-012099BD-D591-44D9-9AAA-ACBB22B91F0B Q21261315-52814CA5-A56C-4C55-B203-BCF9D376DF5D Q24338724-A3AC766D-CFFD-4282-A745-7D2150EC9E07 Q24627306-13271D6A-1B53-41AE-8789-DBBF89B02541 Q24632791-7D835F4F-C8AE-4D3F-B586-6762DA83683F Q24658334-A8479A36-6676-4778-8C42-84F638DB620C Q26766293-5761B384-3746-4550-8479-15FB6A0DDB13 Q26829873-D57D48A1-4C16-4167-B629-F1BBC014AA8C Q26863497-409EFFE3-6CFC-4E70-B0C5-0E0412D44CF5 Q27006099-A0F82FAD-506B-4C91-B167-20237405DFAF Q27012684-D635DE30-E7AF-48CB-B7F3-9E19B660AEEB Q27013006-714931E1-7488-449B-A689-F2B0960AA58D Q27324733-6316BD2D-CEA2-4B09-AB4E-B7695B356EF6 Q27852528-697D49D9-24D7-490F-9373-815DA91E94E1 Q28256247-07826918-B69F-4CFB-A599-DCCBB6F110F5 Q28383083-6262D93B-211E-4A4A-B413-1A1B517C0142 Q28393898-C81998D7-B595-49CD-B2FB-865D5B2220FA Q28475285-43FBBEF1-B5D1-400C-8C93-B11C54981307 Q28741507-3E325C61-092D-47CD-B39A-534C1D623836 Q28743108-198B0FEB-3AFE-4F20-8B26-4B55EEF20707 Q28743461-5B8732CA-EB73-418C-B55C-4AB952144CA4 Q29617506-AB1320CA-5A6F-4E13-A479-6F7A16591211 Q29618030-B16B13C4-3911-4E9F-94EC-F8F1304E5DEE Q30437740-FBAD52BE-0367-44FC-B2A0-46AF1D05A6D6 Q30441231-75F56E9F-35A6-4145-A207-C2F54084C945 Q30684049-EF85C3E1-989E-418B-B786-EE692F3508B5 Q31110612-5501E1C8-888F-42C8-9657-C76080448E8F Q33316159-4060DC1E-A8EE-4203-8634-3D10E5A9F825 Q33357019-0CE4EEC1-AA8E-4737-9583-A5BAEE536BDF Q33385397-06A75EE0-5E5C-4F76-811C-C49C6521FD73 Q33404027-A04D25F5-645A-4F4D-B1A9-19D151495333 Q33419115-4700A9D6-8ADA-44C9-9BBA-75DF7DBE0C39 Q33423176-6BBAB44E-4BDB-468B-B16A-8C8F65897012 Q33426563-EDD51E11-53AC-49F1-8D8E-63883E5B7BDE Q33591658-B4F0960F-C863-4F0C-B006-E82DC1799F09 Q33606604-56DEC415-B28E-40D5-A650-9C881763A93C Q33621327-5345F669-7C7D-4869-B34E-376564707261 Q33727929-61F77856-92D4-46F8-A436-E62380AD2268 Q33747609-E4325EEC-B62C-454B-AF45-122E27123C3E Q33864058-6908D3A4-54D7-4F5E-965E-AEB521661459

P2860

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

http://www.wikidata.org/entity/Q28472048

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@ast

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@en

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@nl

type

label

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@ast

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@en

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@nl

prefLabel

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@ast

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@en

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@nl

P1433

Q28472048-DAC37E82-DAE5-4508-9D3D-4D9485C6CAD9

P1476

Q28472048-7E90BFAA-3A3B-4518-8381-D712FCBBD624

P2093

Q28472048-0A625C15-695C-4482-BEFB-4CCA52800D08

Q28472048-2C62AD11-D136-4F17-9D15-E0B1C2851A27

Q28472048-3235FFDA-493C-4CF3-8C77-24F52775EC93

Q28472048-337AD23D-FCDE-4EEE-B238-C13FE9D36ADD

Q28472048-3AC0C8E0-8FF8-4B5F-A98A-523E3D72B1FA

Q28472048-664AE5B9-0130-4B64-AB51-2D6BEF8C1ACA

Q28472048-6E263704-2485-424E-A0F9-D45CF7085FD4

Q28472048-78A56556-BA8E-41D6-9302-6A6639ED94CE

Q28472048-7A8858FE-0421-4C7A-8464-CF29D9A6F6EC

Q28472048-871540E1-8786-4A9C-A263-BE58D93145B0

P2860

Q28472048-0024AD12-D53D-4DEC-A170-687CE8EB96FF

Q28472048-03499256-B987-4C9A-A266-B4FC5D4A9778

Q28472048-04A16B2B-C8D9-4E88-8D1F-7CF56C07BB04

Q28472048-0B86F6DD-D39F-4AF0-934E-71AC3CA65FD0

Q28472048-15A14430-D428-4835-82D5-07665D062F86

Q28472048-16156D20-2AC2-4FB7-B7EA-6A64A1401379

Q28472048-226A575D-288B-44EE-92AF-51B0F0856BFB

Q28472048-2DD4C6F6-F08A-4952-A25C-07938CFD6339

Q28472048-372F1B6A-8E72-4044-91B3-A1A37E041C5A

Q28472048-3C466A79-FAD9-443C-9787-DD2B6BD2146D

P304

Q28472048-4B9F967E-5A3B-4294-BBEE-75180D84E8D5

P31

Q28472048-AAF9C1B9-C3EE-49ED-874D-FC4321663288

P3181

Q28472048-006D0433-0E96-4BA4-AD09-EE3CACAD27E1

P356

Q28472048-10A0CEC0-8B6B-4BE5-81F3-FB3E75129B33

P407

Q28472048-7A2E7937-8422-4A53-BE20-C0A832FA1236

P433

Q28472048-FE4E38C6-6B39-4781-9EBA-E57D760A7C3F

P478

Q28472048-3C6F27E9-CF8B-4A59-B979-AE1E560E67BD

P50

Q28472048-23848FFE-CF93-469D-993E-0B7B73C4F7D2

Q28472048-45F7F85B-A20F-4AAD-9385-44183EA41E08

P577

Q28472048-35B9372D-EA96-4847-A5DB-2995B8EE4F14

P5875

Q28472048-2DFEB79A-224D-4E5F-B381-DAE9785A1FCE

P698

Q28472048-92292CFD-B14B-4FD7-B62F-F2B635A3C993

P921

Q28472048-E60DF31B-2885-4607-B2A9-44154B9D434C

P932

Q28472048-F265940A-108C-438C-8711-6CE21A741AB3

P3181

P356

JOURNAL.PMED.0050008

P1433

P1476

Antitumor activity of rapamyci ...... nt PTEN-deficient glioblastoma

@en

P2093

Albert Lai

http://www.w3.org/2001/XMLSchema#string

Charles L Sawyers

http://www.w3.org/2001/XMLSchema#string

David Youngkin

http://www.w3.org/2001/XMLSchema#string

Don Becker

http://www.w3.org/2001/XMLSchema#string

Ingo K Mellinghoff

http://www.w3.org/2001/XMLSchema#string

Jeff Trent

http://www.w3.org/2001/XMLSchema#string

Julie Dang

http://www.w3.org/2001/XMLSchema#string

Kevin Brown

http://www.w3.org/2001/XMLSchema#string

Koji Yoshimoto

http://www.w3.org/2001/XMLSchema#string

Linda Liau

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Identification of a proline-rich Akt substrate as a 14-3-3 binding partner

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

TOR signaling in growth and metabolism

Defining the role of mTOR in cancer

Current development of mTOR inhibitors as anticancer agents

P304

e8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

613247

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.0050008

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Phioanh Nghiemphu

P577

2008-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5636832

http://www.w3.org/2001/XMLSchema#string

P698

18215105

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2211560

http://www.w3.org/2001/XMLSchema#string